Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs.
Read articleEnables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs.
ReadOGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx detects clinically relevant rearrangements that occur in patients with acute leukemia, providing a robust, accessible, rapid turnaround test for KMT2Ar detection.
ReadThrough this partnership, SureSeq™ NGS panel users can gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.
ReadOGT will be moving from plastic packaging to new, sustainable packaging for CytoCell products, an important step forward in our ongoing environmental efforts.
ReadUltra-low variant detection (including very large FLT3-ITDs) enables a stronger characterization of a sample’s current AML status.
ReadImproving upon existing SureSeq™ technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples
ReadEnables users to replace multiple techniques with a single streamlined NGS process for faster results.
ReadInvestment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.
ReadNew NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples
ReadEnhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
ReadExpansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
ReadNew leadership will drive OGT’s mission to improve clinical care by partnering with customers.
ReadCytoCell® University offers extensive FISH expertise and reaffirms commitment to customer support and training.
ReadNew integrated website, expanded resources and substantial worldwide support reaffirm partnership and commitment to customers.
ReadIn the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.
ReadLaunch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.
ReadPaper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure® v3 vs traditional array design.
ReadAddition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.
ReadNew content and Interpret NGS analysis software detection capabilities include BCR-ABL and KMT2A-PTD detection.
ReadDuring these unprecedented times, OGT remains committed and ready to support you...
ReadReinforcing collaboration toward the realization of genomic medicine in the area of ophthalmic disorders.
ReadPlasma and tissue sequencing demonstrate clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment.
ReadRobust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.
ReadSureSeq™ CLL + CNV - comprehensive CLL genomic profiling from a single assay.
ReadCytoSure® NGS – Combining the benefits of microarrays and NGS in a single assay.
ReadMDSAP certification of new Cambridge facility smooths path to future IVD approvals.
ReadSureSeq™ complete library preparation solution delivers unparalleled data quality.
ReadState-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.
ReadSysmex demonstrates confidence and investment in OGT and the United Kingdom.
ReadClearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.
ReadThis year, OGT was proud to send CytoCell® Product Manager Alex Hobbs to join the team of Sysmex runners representing Sysmex EMEA, APAC and JEA.
ReadFollowing successful European rollout, more customers to benefit from enhanced local sales and support services.
ReadPowerful, flexible and easy-to-use analysis solution gets the most out of NGS data, helping researchers effortlessly translate cumbersome NGS data into meaningful results.
ReadCustomers to benefit from Sysmex’s extensive operational footprint.
ReadIncreased NGS content, now covering 120 fully optimized cancer related genes, provides even more flexibility for customization.
ReadOn 1st April 2018 Dr John Anson took over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board.
ReadSysmex, a Japanese in vitro diagnostic company, will acquire all of OGT’s shares, gaining access to OGT’s genetic analysis technologies and expertise in the cytogenetics domain.
ReadNew SureSeq myPanel™ NGS Custom Cancer Panel content covers a wider range of cancer types with excellent coverage uniformity for confident results.
ReadAddition of three new sarcoma probes produces largest portfolio on the market.
ReadCytoSure® FH Panels enable streamlined investigation of familial hypercholesterolemia (FH) and customization of content.
ReadSignificant expansion of CytoCell® hematology range underlines OGT's position as the one-stop-shop for high-quality fluorescence in situ hybridization (FISH) probes.
ReadLaunch of SureSeq myPanel™ NGS Custom Cancer Panels provide scientists with completely customized, pre-optimized next generation sequencing (NGS) probe panels relevant to their research.
ReadCytoCell® ROS1 Plus Breakapart and RET Breakapart probes specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer — non-small cell lung cancer (NSCLC).
ReadWorkshop at ESHG explores the power of exon-focused microarrays in enhancing genetic syndrome research.
ReadRange now includes ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe Aqua and Chromosome 15 Alpha Satellite Probe Red.
ReadSureSeq™ FFPE DNA Repair Mix has been optimized to repair a broad range of damage in formalin-fixed, paraffin-embedded (FFPE) derived DNA.
ReadNew CE-IVD labelled CytoCell® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit consistently delivers bright, specific signals with minimal background
ReadNew CytoSure® Constitutional v3 +LOH array delivers comprehensive genetic analysis of developmental delay disorders, with content covering 502 targeted genes.
ReadLicense grants Baylor Miraca use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology.
ReadWhite paper describes the experiences of Dr Tracey Lewis and Dr Emily Farrow with OGT’s CytoSure® Medical Research Exome Array.
ReadStrategic realignment of OGT commercial operations to fuel further growth in its high value genomics products portfolio.
ReadAddition of SureSeq™ Ovarian Cancer Panel and SureSeq NGS Library Preparation Kit to OGT's NGS product range.
ReadNew additions to the CytoCell® range include-quality pathology FISH probes for 1q25, 1p36, 19p13, 19q13, ROS1-GOPC and RET.
ReadThe presentation, entitled ‘The Next Generation of Microarrays: Identifying a Broader Range of Genetic Syndromes Using Exon–Focused Array Designs’, took place at the ESHG conference in Glasgow, UK.
ReadPanel replaces the existing procedure of sequential analysis of single genes, to reduce the time and cost associated with identifying MPNs, a group of diseases that cause abnormal blood cell production.
ReadUnique CytoSure® Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the Deciphering Developmental Disorders (DDD) study data.
ReadLicense gives OGT access to data from the Deciphering Developmental Disorders (DDD) study, which will be used to develop its CytoSure® Constitutional v3 range.
ReadContract is to develop Next Generation Sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK.
ReadOGT teams up with clinical research experts to discuss the role of next generation sequencing (NGS) in cancer medicine.
ReadWhite paper explores how Sheffield Children's NHS Foundation Trust has seamlessly transferred to its CytoSure® ISCA 8x60k platform.
ReadProprietary OGT microarray technology will allow clinical laboratories to utilize existing microarray equipment to offer in-house NIPT.
ReadDeveloped with leading molecular genetics experts at Emory University, the new array is highly targeted and exon-focused, enabling the accurate detection of medical research relevant microdeletions and microduplications.
ReadThe award recognizes OGT’s acquisition of Cambridge-based Cytocell Limited (CytoCell), a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.
ReadLandmark project has the potential to accelerate the diagnosis of cancer and rare diseases, ultimately supporting patient care and research.
ReadThe CytoSure® Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos.
ReadNew and existing CytoCell® customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure.
ReadNew 60-gene next generation sequencing (NGS) hybridization-based enrichment panel offers researchers accurate and reliable solid tumor profiling for both known and novel variants.
ReadNew application note details the technical evaluation of two DNA labeling kits, where OGT’s CytoSure® Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative.
ReadNew white paper provides researchers to discover how, when used alongside sequencing, microarrays play a vital role in delivering accurate detection of point mutations and single exon copy number aberrations.
ReadInnovative new features further facilitate and standardize the data analysis workflow in order to deliver rapid access to meaningful results.
ReadExpanded range of CytoSure® Molecular Arrays now enables detection of CNV in genes associated with over 20 genetic disorders, including cardiovascular, inherited eye, intellectual disability and neuromuscular disorders, as well as a range of inherited cancers.
ReadAcquisition expands OGT’s genomic medicine offering, with CytoCell’s portfolio of fluorescence in situ hybridization (FISH) probes complementing OGT’s CytoSure cytogenetics array and NGS products.
ReadTwo-year agreement for the supply of oligo-based arrays for cytogenetics covers a consortium of four UK NHS Genetics Labs.
ReadPaper investigates the main strategies employed to optimize target enrichment for next generation sequencing (NGS) assays, assisting researchers to make informed decisions when designing studies.
ReadAward recognizes OGT’s collaboration with the Birmingham and Salisbury NHS Regional Genetics Laboratories to develop and launch a 58-gene solid tumor profiling service to advance vital research into personalized cancer care.
ReadNew array allows the simultaneous detection of copy number variation (CNV) and loss of heterozygosity (LOH), with a SNP resolution that enables reporting of LOH at 10Mb.
ReadPaper aims to assist researchers when planning NGS strategies by providing a detailed review of the major re-sequencing methods.
ReadNew array combines long oligo aCGH probes with fully validated SNP content, providing the superior detection of both CNVs and loss of heterozygosity LOH on a single chip.
ReadApp note aims to support researchers in navigating a combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH) on a single array.
ReadThe licence agreement agreed with the Cancer Cytogenomics Microarray Consortium (CCMC) is to design a whole genome, cancer-specific microarray.
ReadNew office enables OGT to provide hands-on technical support and training to its existing US customers, and to take advantage of opportunities to develop the business further.
ReadDatabase is comprised of more than 10 million oligonucleotide probes designed to the latest release of the human genome.
ReadBy utilizing an entirely new relational database design, the software now allows sample data to be stored and analyzed in accordance to its relationship with other data.
ReadArray combines array comparative genomic hybridization (aCGH) probes, endorsed by the International Standards for Cytogenomic Arrays (ISCA) Consortium, with fully validated single nucleotide polymorphism (SNP) content.
ReadCytoSure® Hematological Cancer +SNP array is optimized for the study of the hematological malignancies CLL and Multiple Myeloma, as well as MPN and MDS.
ReadSir Ed becomes one of only four researchers to have received the prize since it was inaugurated in the year 2000.
ReadNew DNA microarrays utilize a unique collection of probes for detecting CNVs within genes associated with a variety of rare disease disorders.
ReadProject aims to develop a tumor profiling assay based on targeted panel enrichment and next generation sequencing (NGS).
ReadProduct range now includes high-throughput genomic DNA labeling kits and sample tracking spike-ins
ReadAccreditation extends to all data generation and security procedures, and acknowledges that data confidentiality, availability and integrity is carefully managed and controlled.
ReadGroundbreaking CytoSure® ISCA UPD 4 x 180k array allows simultaneous detection of DNA copy number variation (CNV) and whole chromosome uniparental disomy (UPD).
ReadOGT's Oxford, UK headquarters has been certified to BS EN ISO 9001:2008 by the British Standards Institution (BSI), one of the world’s leading certification bodies.
ReadOGT's CytoSure® Interpret Software can now seamlessly transfer aCGH aberration data directly to Cartagenia’s Bench™ constitutional cytogenetics platform.
ReadThe three new powerful arrays focus on disease and syndrome-associated genome regions, in addition to offering whole genome coverage.
ReadCytoSure® Interpret software delivers faster and easier translation of oligo aCGH data into meaningful results.
ReadFeaturing a 4x44k format and dense probe coverage of the DMD gene region, this new array offers increased confidence in detecting deletions and duplications within the DMD gene.
ReadThe publication published in Nature is entitled ‘Origins and Functional Impact of Copy Number Variation in the Human Genome.’
ReadThe Center for Human Genetics at Katholieke Universiteit Leuven, Belgium, has begun assessment of OGT's CytoSure® arrays for use in prenatal diagnostic research.
ReadMore than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium have been processed by OGT.
ReadThe Genomic DNA Labelling Kit offers a fast and simple protocol and is optimized for OGT’s CytoSure® family of high resolution oligonucleotide arrays.
ReadOGT and Wellcome Trust Sanger Institute sign collaboration agreement to develop a single platform microarray to test for genetic defects in unborn children.
Read
Visit International site
Visit Canada site
